Medical Minutes


Share

Program Content

Activities

  • Clinical Suspicion for PH
    Medical Minute 1 - It Might be a Zebra: Clinical Suspicion for Primary Hyperoxaluria Type 1
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 26, 2023

    Expires: December 26, 2024

  • Clinical Suspicion for PH
    Medical Minute 1 - It Might be a Zebra: Clinical Suspicion for Primary Hyperoxaluria Type 1
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 26, 2023

    Expires: December 25, 2024

  • Diagnostic Approach to PH
    Medical Minute 2 - Confirming the Suspicion: Diagnostic Approach to Primary Hyperoxaluria Type 1
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 04, 2024

    Expires: January 04, 2025

  • Therapies for PH1
    Medical Minute 3 – Conventional and New Therapies for Primary Hyperoxaluria Type 1
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 16, 2024

    Expires: January 15, 2025

  • Diagnostic Approach to PH
    Medical Minute 2 – Confirming the Suspicion: Diagnostic Approach to Primary Hyperoxaluria Type 1
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 04, 2024

    Expires: January 03, 2025

  • Therapies for PH1
    Medical Minute 3 — Conventional and New Therapies for Primary Hyperoxaluria Type 1
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 16, 2024

    Expires: January 16, 2025

Faculty

cover img faculity

David S. Goldfarb, MD, FASN, FNKF

Clinical Chief
Department of Nephrology
NYU Langone Health
Professor of Medicine & Physiology
NYU Grossman School of Medicine
New York, New York

cover img faculity

John C. Lieske, MD

Professor of Medicine
Mayo Clinic
Division of Nephrology and Hypertension
Rochester, Minnesota

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk